Baiaosetu announced that the company plans to adjust the initial public stock offering project “Early Drug R&D Service Platform Construction Project”, increasing the total investment from 454 million yuan to 462 million yuan, adding 8 million yuan from its own capital. The proposed capital raised amount of 454 million yuan remains unchanged. At the same time, the internal investment structure will be adjusted to adjust the remaining construction project payment form to a leasing model. The date the project reached its intended useable status was extended until June 30, 2027. This adjustment has not changed the investment use, implementation entity, implementation method and implementation location of raised capital, and there is no disguised change in the investment direction of capital raised or harming shareholders' interests. The relevant bill has been reviewed and passed by the company's board of directors, and there is no need to submit it to the shareholders' meeting

Baiaosetu announced that the company plans to adjust the initial public stock offering project “Early Drug R&D Service Platform Construction Project”, increasing the total investment from 454 million yuan to 462 million yuan, adding 8 million yuan from its own capital. The proposed capital raised amount of 454 million yuan remains unchanged. At the same time, the internal investment structure will be adjusted to adjust the remaining construction project payment form to a leasing model. The date the project reached its intended useable status was extended until June 30, 2027. This adjustment has not changed the investment use, implementation entity, implementation method and implementation location of raised capital, and there is no disguised change in the investment direction of capital raised or harming shareholders' interests. The relevant bill has been reviewed and passed by the company's board of directors, and there is no need to submit it to the shareholders' meeting